Article

Molecular Oncogenesis: A Unique Insight'

Research in retinoblastoma and uveal melanoma, two rare ocular cancers, extends beyond ocular oncology to all areas of oncology. Discoveries concerning the mechanisms in those two cancers are shedding light on how other tumors function and may aid in the development of therapies and means of predicting metastasis, according to J. William Harbour, MD, who delivered the Cogan Lecture at the annual meeting of the Association for Research in Vision and Ophthalmology.

May 4

- Fort Lauderdale, FL - Research in retinoblastoma and uveal melanoma, two rare ocular cancers, extends beyond ocular oncology to all areas of oncology. Discoveries concerning the mechanisms in those two cancers are shedding light on how other tumors function and may aid in the development of therapies and means of predicting metastasis, according to J. William Harbour, MD, who delivered the Cogan Lecture at the annual meeting of the Association for Research in Vision and Ophthalmology.

Dr. Harbour, associate professor, and director of the ocular oncology service at Washington University School of Medicine, St. Louis, is the winner of the 2005 Cogan Award for his significant contributions to the understanding of the molecular regulation of the cell cycle in ocular tumors. The Cogan Award recognizes a researcher 40 years or younger at the time of his nomination who has made important contributions to research in ophthalmology and visual science directly related to disorders of the human eye or the visual system.

Dr. Harbour described recent discoveries in oncology research including the activity of the retinoblastoma (Rb) gene mutation, which is present in many other cancers. One important avenue of research that he discussed is the differences in the activity of the Rb protein.

The real revolution started, he pointed out, when investigators began looking at the Rb protein. Virtually every cancer studied has some defect that activates the Rb protein. Further research showed that the Rb protein is regulated differently.

Melanoma and most solid tumors partially inactivate Rb and the tumors proliferate slowly with a low rate of apoptosis; conversely, retinoblastomas, small cell lung cancer, and high-grade melanomas delete Rb and there is rapid proliferation of the tumor with a high rate of apoptosis.

"Retinoblastoma and uveal melanoma provide unique important insights into molecular angiogenesis and have implications far beyond their incidence for cancer biology, developmental biology, and other areas of vision research. Rb research, I believe, will continue to have a profound impact on clinical care both in the area of cancer diagnosis and treatment, hopefully to improve survival, if we can harness the Rb pathway and use it in a controlled way," he concluded.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.